Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-CHOP plus intrathecal methotrexate in CD20+ primary breast diffuse large B-cell lymphoma
KCT0003935Phase 2Active, not recruiting
- Sponsor
- Jeonbuk National University Hospital
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone in diffuse large B-cell lymphoma (DLBCL), sponsored by Jeonbuk National University Hospital. Started Jan 2012; status: active, not recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003935.